PMID- 25841235
OWN - NLM
STAT- MEDLINE
DCOM- 20151217
LR  - 20150924
IS  - 1468-2079 (Electronic)
IS  - 0007-1161 (Linking)
VI  - 99
IP  - 10
DP  - 2015 Oct
TI  - Six-month changes in cytokine levels after intravitreal bevacizumab injection for 
      diabetic macular oedema and macular oedema due to central retinal vein occlusion.
PG  - 1334-40
LID - 10.1136/bjophthalmol-2014-306341 [doi]
AB  - BACKGROUND/AIMS: This study evaluated the impact of intravitreal injection of 
      bevacizumab (IVB) on the microenvironment of the eyes of diabetic macular oedema 
      (DMO) and macular oedema due to central retinal vein occlusion (CRVO-MO) 
      patients. METHODS: This study comprised 136 patients, including 51 patients in 
      the DMO group, 70 in the CRVO-MO group and 15 in the control group, who were 
      followed for 6 months after IVB. Angiogenic cytokines, inflammatory cytokines and 
      growth factors concentrations in the aqueous humour were measured before and 
      after IVB using suspension array technology. We compared the levels of cytokines 
      among DMO patients, CRVO-MO patients and control patients. We compared the levels 
      of cytokines among groups according to the interval between the first and second 
      injections of bevacizumab and according to the number of injections received 
      during the 6-month follow-up period. RESULTS: Significantly higher concentrations 
      of vascular endothelial growth factor (VEGF), transforming growth factor beta 
      (TGF-beta), hepatocyte growth factor (HGF), interleukin 6 (IL-6), serum amyloid A 
      (SAA) and monocyte chemoattractant protein-1 (MCP-1) were found in the aqueous 
      humour of DMO and CRVO-MO patients compared with cataract patients. One month 
      after IVB, the intraocular concentrations of VEGF were significantly decreased in 
      the eyes of DMO (p=0.045) and CRVO-MO (p=0.002) patients compared with baseline. 
      No other cytokine was significantly altered by bevacizumab therapy. CONCLUSIONS: 
      Angiogenic, inflammatory and growth factors are involved in the development of 
      DMO and CRVO-MO. In addition to VEGF, IVB did not cause significant differences 
      in other inflammatory cytokines and growth factors in DMO and CRVO-MO patients.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://group.bmj.com/group/rights-licensing/permissions.
FAU - Wen, Jing
AU  - Wen J
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing, China 
      Key Laboratory of Vision Loss and Restoration (Peking University), Ministry of 
      Education, Beijing, China Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, Beijing, China.
FAU - Jiang, Yanrong
AU  - Jiang Y
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing, China 
      Key Laboratory of Vision Loss and Restoration (Peking University), Ministry of 
      Education, Beijing, China Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, Beijing, China.
FAU - Zheng, Xiaoxue
AU  - Zheng X
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing, China 
      Key Laboratory of Vision Loss and Restoration (Peking University), Ministry of 
      Education, Beijing, China Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, Beijing, China.
FAU - Zhou, Ying
AU  - Zhou Y
AD  - Department of Ophthalmology, Peking University People's Hospital, Beijing, China 
      Key Laboratory of Vision Loss and Restoration (Peking University), Ministry of 
      Education, Beijing, China Beijing Key Laboratory of Diagnosis and Therapy of 
      Retinal and Choroid Diseases, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150403
PL  - England
TA  - Br J Ophthalmol
JT  - The British journal of ophthalmology
JID - 0421041
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Cytokines)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Angiogenesis Inhibitors/administration & dosage
MH  - Aqueous Humor/*metabolism
MH  - Bevacizumab/*administration & dosage
MH  - Cytokines/*metabolism
MH  - Diabetic Retinopathy/*complications/drug therapy/metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/*drug therapy/etiology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Retinal Vein Occlusion/*complications/drug therapy/metabolism
MH  - Retrospective Studies
MH  - Time Factors
MH  - Visual Acuity
OTO - NOTNLM
OT  - Retina
OT  - Treatment Medical
EDAT- 2015/04/05 06:00
MHDA- 2015/12/19 06:00
CRDT- 2015/04/05 06:00
PHST- 2014/11/04 00:00 [received]
PHST- 2015/03/12 00:00 [accepted]
PHST- 2015/04/05 06:00 [entrez]
PHST- 2015/04/05 06:00 [pubmed]
PHST- 2015/12/19 06:00 [medline]
AID - bjophthalmol-2014-306341 [pii]
AID - 10.1136/bjophthalmol-2014-306341 [doi]
PST - ppublish
SO  - Br J Ophthalmol. 2015 Oct;99(10):1334-40. doi: 10.1136/bjophthalmol-2014-306341. 
      Epub 2015 Apr 3.